Overall, SGLT-2 inhibitors slow the decline in kidney function, reduce proteinuria levels, and significantly improve kidney outcomes in patients with diabetic nephropathy and CKD (93). The gene discussed is SLC5A2; the disease is diabetic kidney disease.